---
audienceLevel: patient
cancerTypes:
- lung
- skin
- liver
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Atezolizumab and Hyaluronidase-tqjs - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/atezolizumab-and-hyaluronidase-tqjs
version: v1
---

# Atezolizumab and Hyaluronidase-tqjs - NCI

# Atezolizumab and Hyaluronidase-tqjs

Placeholder slot

(A-teh-zoh-LIZ-yoo-mab â€¦ HY-al-yoo-RAH-nih-days)

Atezolizumab and hyaluronidase-tqjs works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells. Hyaluronidase is a recombinant human form of an enzyme that breaks down a substance in the body called hyaluronic acid. This increases the absorption of drugs into tissue. Atezolizumab and hyaluronidase-tqjs is a form of atezolizumab that is given as an injection under the skin. This form can be given in less time than atezolizumab, which is given through a vein. Atezolizumab and hyaluronidase-tqjs is a type of immunotherapy drug called an immune checkpoint inhibitor.

US Brand Name(s)

Tecentriq Hybreza

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f&audience=consumer)

## Use in Cancer

Atezolizumab and hyaluronidase-tqjs
is approved to be used alone or with other drugs to treat adults with:

- **[Alveolar soft part sarcoma](/Common/PopUps/popDefinition.aspx?id=641933&version=Patient&language=English)** that has spread to other parts of the body or cannot be removed by surgery.
- **[Hepatocellular carcinoma](/Common/PopUps/popDefinition.aspx?id=46363&version=Patient&language=English)** (a type of [liver cancer](/Common/PopUps/popDefinition.aspx?id=44242&version=Patient&language=English)) that has spread to other parts of the body or cannot be removed by surgery. It is used with [bevacizumab](/Common/PopUps/popDefinition.aspx?id=781154&version=Patient&language=English) in adults who have not received [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).
- **[Melanoma](/Common/PopUps/popDefinition.aspx?id=45135&version=Patient&language=English)** that has a certain [mutation](/Common/PopUps/popDefinition.aspx?id=46063&version=Patient&language=English) in the *[BRAF](/Common/PopUps/popDefinition.aspx?id=561325&version=Patient&language=English)* gene. Atezolizumab and hyaluronidase-tqjs is used with [cobimetinib fumarate](/Common/PopUps/popDefinition.aspx?id=776875&version=Patient&language=English) and [vemurafenib](/Common/PopUps/popDefinition.aspx?id=702051&version=Patient&language=English) in adults whose cancer has spread to other parts of the body or cannot be removed by surgery.
- **[Non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English).** Atezolizumab and hyaluronidase-tqjs is used:
- alone after surgery and [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English) chemotherapy in adults with [stage IIA](/Common/PopUps/popDefinition.aspx?id=45357&version=Patient&language=English), [stage IIB](/Common/PopUps/popDefinition.aspx?id=682419&version=Patient&language=English), or [stage IIIA cancer](/Common/PopUps/popDefinition.aspx?id=45367&version=Patient&language=English) that has the [PD-L1](/Common/PopUps/popDefinition.aspx?id=797389&version=Patient&language=English) [protein](/Common/PopUps/popDefinition.aspx?id=46092&version=Patient&language=English)
- alone as the first treatment in adults whose cancer has spread to other parts of the body, has the PD-L1 protein, and does not have a mutation in the *[EGFR](/Common/PopUps/popDefinition.aspx?id=44397&version=Patient&language=English)* gene or *[ALK](/Common/PopUps/popDefinition.aspx?id=721252&version=Patient&language=English)* gene
- with bevacizumab, [paclitaxel](/Common/PopUps/popDefinition.aspx?id=45258&version=Patient&language=English), and [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=Patient&language=English) or [paclitaxel albumin-stabilized nanoparticle formulation](/Common/PopUps/popDefinition.aspx?id=507600&version=Patient&language=English) and carboplatin as the first treatment in adults with non-[squamous](/Common/PopUps/popDefinition.aspx?id=46056&version=Patient&language=English) cancer that does not have a mutation in the *EGFR* gene or *ALK* gene that has spread to other parts of the body
- with paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as the first treatment in patients with non-squamous cancer that does not have an abnormal *EGFR* gene or *ALK* gene and has spread to other parts of the body
- alone in adults whose cancer has spread to other parts of the body and got worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the *[EGFR](/Common/PopUps/popDefinition.aspx?id=44397&version=Patient&language=English)* gene or *[ALK](/Common/PopUps/popDefinition.aspx?id=721252&version=Patient&language=English)* gene, atezolizumab is used if their cancer has gotten worse after treatment with [FDA](/Common/PopUps/popDefinition.aspx?id=454786&version=Patient&language=English)-approved therapy for these mutations.
- **[Small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45327&version=Patient&language=English).** Atezolizumab and hyaluronidase-tqjs is used with carboplatin and [etoposide](/Common/PopUps/popDefinition.aspx?id=45189&version=Patient&language=English) as the first treatment in adults with [extensive-stage](/Common/PopUps/popDefinition.aspx?id=45911&version=Patient&language=English) cancer.

For information about atezolizumab that may apply to atezolizumab and hyaluronidase-tqjs, see the Drug Information Summary for [Atezolizumab](/about-cancer/treatment/drugs/atezolizumab).

Atezolizumab and hyaluronidase-tqjs
is also being studied in the treatment of other types of
cancer.

## More About Atezolizumab and Hyaluronidase-tqjs

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/809887) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Atezolizumab and Hyaluronidase-tqjs](https://medlineplus.gov/druginfo/meds/a616035.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

[Immune Checkpoint Inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Atezolizumab And Hyaluronidase-tqjs](https://www.cancer.gov/research/participate/clinical-trials/intervention/C186549) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
